Literature DB >> 11181680

Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base.

R Yancik1, P A Ganz, C G Varricchio, B Conley.   

Abstract

Not only do persons 65 years and older bear a disproportionate burden of cancer, advancing age is associated with increased vulnerability to other age-related health problems. Newly diagnosed older cancer patients who have lived into later years of life may have concurrent ailments (eg, diabetes, chronic obstructive pulmonary disease, heart disease, arthritis, and/or hypertension) that could affect treatment choice, prognosis, and survival. The clinician must often make cancer treatment decisions in the context of an older individual's pre-existing health problems (ie, comorbidity). Ways to produce reliable information on comorbidity that can be effectively used in evaluation of older cancer patients are urgently needed. What is the nature and severity of the older patient's comorbid health problems? How do other age-related conditions influence treatment decisions and the cancer course? How do already compromised older patients tolerate the stress of cancer and its treatment? How are concomitant comorbid conditions managed? At present, no established, valid way to assess comorbidity in older cancer patients exists. Such technology, with a solid conceptual and scientific base, promises a high positive clinical yield to assure quality cancer care for older patients if reliable and valid instruments can be integrated into oncology practice. Much preliminary scientific work must be performed. A synthesis of viewpoints on what to include in comorbidity assessment of older cancer patients and development approaches were expressed in a multidisciplinary working group convened by the National Institute on Aging and the National Cancer Institute. We share the key issues raised regarding complexities of comorbidity assessment and suggestions for scientific inquiry.

Entities:  

Mesh:

Year:  2001        PMID: 11181680     DOI: 10.1200/JCO.2001.19.4.1147

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  67 in total

1.  [The significance of comorbidity and age in radical prostatectomy].

Authors:  M Wirth; M Fröhner
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

Review 2.  Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.

Authors:  Bella Pajares; Esperanza Torres; José Manuel Trigo; María Isabel Sáez; Nuria Ribelles; Begoña Jiménez; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

3.  Evaluating the Completeness of the SEER-Medicare Linked Database for Oral and Pharyngeal Cancer.

Authors:  Jonathan D Mahnken; John D Keighley; Christopher G Cumming; Douglas A Girod; Matthew S Mayo
Journal:  J Registry Manag       Date:  2008-01-01

4.  Educating health care professionals to provide institutional changes in cancer survivorship care.

Authors:  Marcia Grant; Denice Economou; Betty Ferrell; Gwen Uman
Journal:  J Cancer Educ       Date:  2012-06       Impact factor: 2.037

5.  Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy.

Authors:  Matti S Aapro; David C Dale; Michael Blasi; Brenda Sarokhan; Fawzia Ahmed; Richard C Woodman
Journal:  Support Care Cancer       Date:  2006-06-07       Impact factor: 3.603

Review 6.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 7.  Methodology, design, and analytic techniques to address measurement of comorbid disease.

Authors:  Timothy L Lash; Vincent Mor; Darryl Wieland; Luigi Ferrucci; William Satariano; Rebecca A Silliman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-03       Impact factor: 6.053

8.  Self-reported medical morbidity among informal caregivers of chronic illness: the case of cancer.

Authors:  Youngmee Kim; Charles S Carver; Rachel S Cannady; Kelly M Shaffer
Journal:  Qual Life Res       Date:  2012-08-21       Impact factor: 4.147

9.  A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.

Authors:  Robert U Newton; Dennis R Taaffe; Nigel Spry; Robert A Gardiner; Gregory Levin; Bradley Wall; David Joseph; Suzanne K Chambers; Daniel A Galvão
Journal:  BMC Cancer       Date:  2009-06-29       Impact factor: 4.430

10.  A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.

Authors:  Daniel A Galvão; Nigel Spry; Dennis R Taaffe; James Denham; David Joseph; David S Lamb; Greg Levin; Gillian Duchesne; Robert U Newton
Journal:  BMC Cancer       Date:  2009-12-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.